Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 97.19% is 80% above its 5-year average of 54.03%, near the high end of its 5-year range (-994.20%–100.00%).
165.15% above its 12-month average of -149.18%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 97.77%.
GROSS MARGIN
97.19%
GROSS MARGIN AVG TTM
-149.18%
GROSS MARGIN AVG 3Y
38.93%
GROSS MARGIN AVG 5Y
54.03%
GROSS MARGIN AVG 10Y
53.52%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+165.15%
CURRENT VS 3Y AVG
+149.66%
CURRENT VS 5Y AVG
+79.88%
CURRENT VS 10Y AVG
+81.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+134.87%
vs the sector median at left
MeiraGTx Holdings plc
Market Cap
$976.80M
Gross Margin
97.19%
TTM Avg
-149.18%
3Y Avg
38.93%
5Y Avg
54.03%
Market Cap
$978.73M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$969.12M
Gross Margin
79.21%
TTM Avg
77.54%
3Y Avg
74.46%
5Y Avg
74.10%
Market Cap
$992.10M
Gross Margin
63.74%
TTM Avg
62.39%
3Y Avg
56.59%
5Y Avg
42.69%
Market Cap
$1.00B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$954.07M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
50.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $976.80M | 97.19% | -149.18% | 38.93% | 54.03% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $978.73M | 0.00% | 0.00% | 0.00% | 0.00% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $981.10M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $969.12M | 79.21% | 77.54% | 74.46% | 74.10% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $992.10M | 63.74% | 62.39% | 56.59% | 42.69% |
| Vor Biopharma Inc. (VOR)vs › | $992.39M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | 0.00% | 0.00% | 0.00% | 16.67% |
| Aktis Oncology, Inc. (AKTS)vs › | $954.07M | 100.00% | 100.00% | 50.00% | 50.00% |
| Savara Inc. (SVRA)vs › | $951.89M | 0.00% | 0.00% | 0.00% | -2255.58% |
| Immatics N.V. (IMTX)vs › | $1.01B | 100.00% | 100.00% | 100.00% | 64.23% |
Gross Margin
97.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 97.77% |
| 2026-03-31 | -994.20% |
| 2025-12-31 | 99.37% |
| 2025-09-30 | 23.66% |
| 2025-06-30 | 27.50% |
| 2025-03-31 | 28.45% |
| 2024-12-31 | 44.81% |
| 2024-09-30 | -9.85% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | -369.87% |
| 2023-12-31 | -91.76% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 8.28% |
| 2023-03-31 | 7.26% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 57.89% |
| 2022-06-30 | 80.62% |
| 2022-03-31 | 62.40% |
| 2021-12-31 | 90.20% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
